Author Archives: Isaura Santos

Digestive System Involvement in Scleroderma

In this video from the Scleroderma Foundation, learn from Dinesh Khanna, MD, MS, about the gut involvement (also called digestive system or gastrointestinal involvement) in scleroderma and how it can affect up to 95 percent of people suffering from the disease. This lecture from the 2015 Scleroderma Foundation National…

North American Nonprofits Partnering To Create Awareness For Scleroderma

Three leading organizations focused on scleroderma advocacy and research are partnering during June’s Scleroderma Awareness Month in order to boost awareness and compassion for those who suffer from the disease and their families. The Scleroderma Foundation, Scleroderma Research Foundation and Scleroderma Society of Canada are the primary partners in the effort. This…

Fibrocell Receives Rare Pediatric Disease Designation For FCX-007 To Treat Dystrophic Epidermolysis Bullosa (RDEB)

Fibrocell Science, Inc., an autologous gene and cell therapy firm developing first-in-class treatments to address scleroderma and connective tissue-related diseases, recently announced that the United States Food and Drug Administration (FDA) has awarded a rare pediatric disease designation for FCX-007. This is the Fibrocell’s main orphan gene-therapy drug candidate to treat recessive dystrophic epidermolysis bullosa…

SPARC Consortium Supports Research In Scleroderma

The Strategic Pharma-Academic Research Consortium for Translational Medicine has announced it is providing new grants that will support research into autoimmune diseases worth $1.9 million in total. The consortium is led by the Indiana Clinical and Translational Sciences Institute and is offering financial support for research projects involving scleroderma, dermatomyositis, lupus, multiple sclerosis and Crohn’s disease. Other…

Fibrocell Science Reports First Quarter 2015 Financial And Operating Results On Friday, May 8, 2015

Fibrocell Science, Inc., a company focused on autologous cell and gene therapy that is developing top treatments to address rare and life-threatening skin and connective tissue illnesses, has announced that it will report its first quarter 2015 results next Friday, May 8, 2015. The report will be made available to the public before the United States financial markets…

Pivotal Scleroderma STAR Trial Expansion Approved By the FDA

Cytori Therapeutics, Inc. recently announced an FDA approval that will allow them to expand the number of sites in the United States from 12 to 20 centers where the company’s Scleroderma clinical trials are currently being conducted. The STAR study was approved by the FDA in January 2015 as an 80-patient…

Cytori Receives Positive European Opinion on Scleroderma Orphan Drug Status

Cytori Therapeutics, Inc. recently announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has given a positive opinion concerning Cytori’s submission for an orphan drug designation for ECCS-50, the company’s experimental Scleroderma therapeutic, which is based on stromal vascular fraction cells, from adipose tissue and derived from Celution® System,…